FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387334513> ?p ?o ?g. }

• W4387334513 abstract "Non-T2 asthma is characterized by the absence of elevated type 2 inflammatory biomarkers such as blood-eosinophils, total and allergen-specific Immunoglobulin E and Fractional exhaled Nitric Oxide (FeNO). According to guidelines, inhaled corticosteroids (ICS) are the cornerstone of asthma management. However, ICS treatment is associated with a risk of local side effects, including hoarseness and thrush, and long-term high-dose therapy may cause systemic adverse effects. Furthermore, whereas treatment with ICS is highly effective in T2 asthma, studies have shown a markedly reduced ICS efficacy in patients with a lower degree of T2 inflammation, thus posing a clinical challenge in this subgroup of patients. Hence, owing to the ICS dosage step-up approach in current clinical guidelines, patients with low T2 biomarkers are at risk of being exposed to high doses of ICS, and by that at risk of side effects. Thus, an ICS-treatment regime guided by biomarkers that reflects the inflammatory phenotype is warranted in order to reduce the corticosteroid burden in patients with non-T2 asthma. This study combines a panel of non-T2 inflammatory markers (low periostin, low blood-eosinophils, and low FeNO), to determine if this group of patients can maintain asthma control during ICS withdrawal.This is an ongoing prospective multicenter open-label randomized, controlled trial aiming to assess if ICS can be safely tapered in patients with non-T2 asthma. The patients are randomized 1:1 to either standard of care or an ICS tapering regimen (n = 55 in each group) where the initial ICS dose is reduced by 50% for 8 weeks followed by total ICS removal. The primary endpoint is change in asthma control questionnaire (ACQ) from baseline to post-tapered ICS. The secondary endpoints are time from baseline to drop-out caused by loss of asthma control, changes in serum-periostin, blood-eosinophils, FeNO, Forced Expiratory Volume in 1 s (FEV1) and in sputum-eosinophils.This study aims to provide data on ICS tapering in non-T2 asthma patients and to contribute to a more individualized and corticosteroid-sparing treatment regime in this group of patients.Clinicaltrials.gov Identifier: NCT03141424. Registration date: May 5th, 2017." @default.
• W4387334513 created "2023-10-05" @default.
• W4387334513 creator A5019652338 @default.
• W4387334513 creator A5030903757 @default.
• W4387334513 creator A5055672763 @default.
• W4387334513 creator A5075123551 @default.
• W4387334513 date "2023-10-04" @default.
• W4387334513 modified "2023-10-07" @default.
• W4387334513 title "Biomarker-guided withdrawal of inhaled corticosteroids in asthma patients with a non-T2 inflammatory phenotype – a randomized controlled trial study protocol" @default.
• W4387334513 cites W1993997407 @default.
• W4387334513 cites W1995033048 @default.
• W4387334513 cites W1997095217 @default.
• W4387334513 cites W2053208368 @default.
• W4387334513 cites W2063801679 @default.
• W4387334513 cites W2085902327 @default.
• W4387334513 cites W2095754126 @default.
• W4387334513 cites W2106117449 @default.
• W4387334513 cites W2108919922 @default.
• W4387334513 cites W2109795756 @default.
• W4387334513 cites W2110052844 @default.
• W4387334513 cites W2110534370 @default.
• W4387334513 cites W2111609315 @default.
• W4387334513 cites W2132430943 @default.
• W4387334513 cites W2137275746 @default.
• W4387334513 cites W2145977358 @default.
• W4387334513 cites W2146887625 @default.
• W4387334513 cites W2156136186 @default.
• W4387334513 cites W2163441905 @default.
• W4387334513 cites W2167829087 @default.
• W4387334513 cites W2315357669 @default.
• W4387334513 cites W2510188126 @default.
• W4387334513 cites W2511120040 @default.
• W4387334513 cites W2562179046 @default.
• W4387334513 cites W2593423078 @default.
• W4387334513 cites W2730218169 @default.
• W4387334513 cites W2752584372 @default.
• W4387334513 cites W2778241967 @default.
• W4387334513 cites W2790946150 @default.
• W4387334513 cites W2885060981 @default.
• W4387334513 cites W2945395559 @default.
• W4387334513 cites W2957444086 @default.
• W4387334513 cites W2998849120 @default.
• W4387334513 cites W3084228319 @default.
• W4387334513 cites W3106796183 @default.
• W4387334513 cites W3212323022 @default.
• W4387334513 cites W4224947560 @default.
• W4387334513 cites W4280588693 @default.
• W4387334513 cites W4317773660 @default.
• W4387334513 doi "https://doi.org/10.1186/s12890-023-02679-y" @default.
• W4387334513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37794472" @default.
• W4387334513 hasPublicationYear "2023" @default.
• W4387334513 type Work @default.
• W4387334513 citedByCount "0" @default.
• W4387334513 crossrefType "journal-article" @default.
• W4387334513 hasAuthorship W4387334513A5019652338 @default.
• W4387334513 hasAuthorship W4387334513A5030903757 @default.
• W4387334513 hasAuthorship W4387334513A5055672763 @default.
• W4387334513 hasAuthorship W4387334513A5075123551 @default.
• W4387334513 hasBestOaLocation W43873345131 @default.
• W4387334513 hasConcept C126322002 @default.
• W4387334513 hasConcept C168563851 @default.
• W4387334513 hasConcept C185592680 @default.
• W4387334513 hasConcept C189165786 @default.
• W4387334513 hasConcept C197934379 @default.
• W4387334513 hasConcept C2776042228 @default.
• W4387334513 hasConcept C2776804153 @default.
• W4387334513 hasConcept C2777699602 @default.
• W4387334513 hasConcept C2780333948 @default.
• W4387334513 hasConcept C2781142857 @default.
• W4387334513 hasConcept C2781197716 @default.
• W4387334513 hasConcept C2781413609 @default.
• W4387334513 hasConcept C55493867 @default.
• W4387334513 hasConcept C71924100 @default.
• W4387334513 hasConcept C86803240 @default.
• W4387334513 hasConcept C95444343 @default.
• W4387334513 hasConceptScore W4387334513C126322002 @default.
• W4387334513 hasConceptScore W4387334513C168563851 @default.
• W4387334513 hasConceptScore W4387334513C185592680 @default.
• W4387334513 hasConceptScore W4387334513C189165786 @default.
• W4387334513 hasConceptScore W4387334513C197934379 @default.
• W4387334513 hasConceptScore W4387334513C2776042228 @default.
• W4387334513 hasConceptScore W4387334513C2776804153 @default.
• W4387334513 hasConceptScore W4387334513C2777699602 @default.
• W4387334513 hasConceptScore W4387334513C2780333948 @default.
• W4387334513 hasConceptScore W4387334513C2781142857 @default.
• W4387334513 hasConceptScore W4387334513C2781197716 @default.
• W4387334513 hasConceptScore W4387334513C2781413609 @default.
• W4387334513 hasConceptScore W4387334513C55493867 @default.
• W4387334513 hasConceptScore W4387334513C71924100 @default.
• W4387334513 hasConceptScore W4387334513C86803240 @default.
• W4387334513 hasConceptScore W4387334513C95444343 @default.
• W4387334513 hasFunder F4320323462 @default.
• W4387334513 hasFunder F4320325003 @default.
• W4387334513 hasIssue "1" @default.
• W4387334513 hasLocation W43873345131 @default.
• W4387334513 hasLocation W43873345132 @default.
• W4387334513 hasOpenAccess W4387334513 @default.
• W4387334513 hasPrimaryLocation W43873345131 @default.
• W4387334513 hasRelatedWork W2005818888 @default.
• W4387334513 hasRelatedWork W2138787051 @default.

• next